<DOC>
	<DOCNO>NCT01474434</DOCNO>
	<brief_summary>This study design evaluate potential pradigastat ( LCQ908 ) impact cardiovascular risk .</brief_summary>
	<brief_title>Efficacy LCQ908 Cardiovascular Risk</brief_title>
	<detailed_description>This study 2 part . Part A multicenter , double-blind , randomize , placebo-controlled , non-confirmatory crossover study assess response high-fat meal challenge set pradigastat versus placebo . Part A 2 cohort i.e . Cohort 1 patient stable coronary artery disease hypertriglyceridemia Cohort 2 patient asymptomatic non-obstructive coronary artery disease elevate coronary heart disease risk hypertriglyceridemia . Part B double blind phase design assess response three month chronic treatment pradigastat versus placebo normal diet . The trial terminate interim analysis Part A , Cohort 1 . The interim analysis result indicate high-fat meal challenge induce impairment either myocardial perfusion reserve index ( MPRi ) exercise treadmill performance . Part B never start .</detailed_description>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Hypertriglyceridemia</mesh_term>
	<criteria>History coronary artery disease Elevated triglycerides On medication help lower cholesterol Poorly control diabetic patient and/or change diabetic medication within 12 week screen History myocardial infarction ( heart attack ) within 6 month screen History procedure open block coronary artery within 12 month enrollment History Coronary Artery Bypass Graft ( CABG ) surgery History congestive heart failure History significant heart valve disease</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>coronary artery disease ,</keyword>
	<keyword>LCQ908 ,</keyword>
	<keyword>hyperlipidemia ,</keyword>
	<keyword>hypertriglyceridemia ,</keyword>
	<keyword>pradigastat</keyword>
</DOC>